Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-27 5:42 pm Sale | 2025-07-01 | 13D | Inozyme Pharma, Inc. INZY | Pivotal bioVenture Partners Fund I, L.P. | 0 0.000% | -4,494,851 (Position Closed) | Filing History |
| 2025-08-14 12:38 pm Sale | 2025-06-30 | 13G | Inozyme Pharma, Inc. INZY | Beryl Capital Management LLC | 0 0.000% | -6,321,584 (Position Closed) | Filing History |
| 2025-08-13 4:31 pm Sale | 2025-06-30 | 13G | Inozyme Pharma, Inc. INZY | Rock Springs Capital Management LP | 0 0.000% | -3,681,174 (Position Closed) | Filing History |
| 2025-08-12 09:02 am Unchanged | 2025-06-30 | 13G | Inozyme Pharma, Inc. INZY | Adage Capital Management, L.P. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2025-07-17 7:54 pm Sale | 2025-06-30 | 13G | Inozyme Pharma, Inc. INZY | BlackRock Inc. BLK | 2,663,678 4.100% | -827,558 (-23.70%) | Filing History |
| 2025-06-04 5:09 pm Purchase | 2025-05-28 | 13G | Inozyme Pharma, Inc. INZY | Glazer Capital, LLC | 4,251,940 6.590% | 4,251,940 (New Position) | Filing History |
| 2025-05-30 5:24 pm Sale | 2025-05-20 | 13G | Inozyme Pharma, Inc. INZY | Affinity Healthcare Fund, LP | 1,867,710 2.890% | -2,104,608 (-52.98%) | Filing History |
| 2025-05-23 4:22 pm Purchase | 2025-05-16 | 13G | Inozyme Pharma, Inc. INZY | Beryl Capital Management LLC | 6,321,584 9.800% | 6,321,584 (New Position) | Filing History |
| 2025-04-23 10:28 am Sale | 2024-12-31 | 13G | Inozyme Pharma, Inc. INZY | Eventide Asset Management, LLC | 2,220,000 3.460% | -1,914,436 (-46.30%) | Filing History |
| 2025-02-14 1:59 pm Sale | 2024-12-31 | 13G | Inozyme Pharma, Inc. INZY | SAMLYN CAPITAL, LLC | 0 0.000% | -3,372,558 (Position Closed) | Filing History |
| 2024-12-09 4:14 pm Purchase | 2024-12-02 | 13G | Inozyme Pharma, Inc. INZY | Affinity Healthcare Fund, LP | 3,972,318 6.180% | 3,972,318 (New Position) | Filing History |
| 2024-11-14 12:19 pm Purchase | 2024-09-30 | 13G | Inozyme Pharma, Inc. INZY | Eventide Asset Management, LLC | 4,134,436 6.440% | 954,599 (+30.02%) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Inozyme Pharma, Inc. INZY | BlackRock Inc. BLK | 3,491,236 5.600% | 0 (Unchanged) | Filing History |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | Inozyme Pharma, Inc. INZY | BlackRock Inc. BLK | 3,491,236 5.600% | 3,491,236 (New Position) | Filing History |
| 2024-02-20 7:11 pm Purchase | 2023-07-28 | 13D | Inozyme Pharma, Inc. INZY | Sofinnova Venture Partners X L.P. | 4,280,308 6.900% | 2,252,000 (+111.03%) | Filing History |
| 2024-02-14 8:34 pm Sale | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | Venrock Healthcare Capital Partners II, L.P. | 0 0.000% | -3,867,749 (Position Closed) | Filing History |
| 2024-02-14 6:08 pm Sale | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | New Enterprise Associates 15, L.P. | 0 0.000% | -2,437,689 (Position Closed) | Filing History |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | BAKER BROS. ADVISORS LP | 0 0.000% | -2,168,000 (Position Closed) | Filing History |
| 2024-02-14 2:10 pm Purchase | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | Rock Springs Capital Management LP | 3,681,174 5.960% | 595,147 (+19.29%) | Filing History |
| 2024-02-14 1:40 pm Purchase | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | SAMLYN CAPITAL, LLC | 3,372,558 5.500% | 3,372,558 (New Position) | Filing History |